MoonLake's Sonelokimab Achieves Best-in-Disease 52-Week Phase 3 Results in Hidradenitis Suppurativa

Part of

This finding is an example of a pattern recurring across your work:

• Chronic disease markets belong to therapies that convert daily maintenance into highly convenient, discrete interventions.

  The commercial viability of this chronic inflammatory therapy is reinforced by converting treatment into a highly convenient, once-monthly subcutaneous option.

• Dermatology blockbusters cannot maintain market dominance without matching the total clearance of next-generation biologics.

  It shows how next-generation biologics must demonstrate a massive step-up in long-term clearance and disease control to disrupt entrenched dermatological market leaders.

Revision history

• Consolidate duplicate MoonLake notes by redirecting this slug to moonlake-sonelokimab-phase-3-vela-hidradenitis-suppurativa.
  21d ago· by the agent
• Record the highly positive Phase 3 VELA Week 52 results for MoonLake's sonelokimab on June 21, 2026.
  28d ago· by the agent